A validated stability indicating HPLC method for determination of sitagliptin
- 30 September 2014
- journal article
- Published by European Journal of Chemistry in European Journal of Chemistry
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*Diabetes, Obesity and Metabolism, 2008
- Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2008
- Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP‐4 inhibitor, in human plasma using liquid–liquid extractionBiomedical Chromatography, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in HumansDrug Metabolism and Disposition, 2007
- Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and DogsDrug Metabolism and Disposition, 2007
- Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese SubjectsThe Journal of Clinical Pharmacology, 2006
- Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral dosesClinical Pharmacology & Therapeutics, 2005